Certara (NASDAQ:CERT) Stock Price Down 7% – What’s Next?

Certara, Inc. (NASDAQ:CERT)’s share price was down 7% during mid-day trading on Wednesday . The company traded as low as $6.65 and last traded at $6.6650. 1,767,528 shares were traded during mid-day trading, a decline of 52% from the average daily volume of 3,701,465 shares. The stock had previously closed at $7.17.

Analyst Upgrades and Downgrades

CERT has been the subject of several recent analyst reports. BMO Capital Markets cut their price target on shares of Certara from $7.00 to $6.00 and set a “market perform” rating for the company in a report on Tuesday, May 12th. Morgan Stanley decreased their price objective on shares of Certara from $11.00 to $10.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 12th. Stephens dropped their target price on shares of Certara from $10.00 to $9.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. KeyCorp cut their target price on shares of Certara from $10.00 to $8.00 and set an “overweight” rating for the company in a research note on Monday, April 13th. Finally, Robert W. Baird reduced their price target on shares of Certara from $7.00 to $6.00 and set a “neutral” rating for the company in a research report on Tuesday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Certara has a consensus rating of “Hold” and a consensus target price of $8.85.

Certara Price Performance

The company has a debt-to-equity ratio of 0.28, a current ratio of 1.88 and a quick ratio of 1.88. The stock has a market capitalization of $1.06 billion, a price-to-earnings ratio of -67.85 and a beta of 1.46. The stock has a 50 day moving average price of $5.68 and a 200-day moving average price of $6.78.

Certara (NASDAQ:CERT) last posted its quarterly earnings results on Monday, May 11th. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.11 by ($0.02). The business had revenue of $106.92 million during the quarter, compared to analysts’ expectations of $106.13 million. Certara had a positive return on equity of 3.52% and a negative net margin of 3.60%.The business’s quarterly revenue was up .8% on a year-over-year basis. During the same period in the prior year, the business posted $0.14 earnings per share. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. On average, analysts forecast that Certara, Inc. will post 0.24 earnings per share for the current year.

Hedge Funds Weigh In On Certara

Several institutional investors and hedge funds have recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Certara by 2,733.3% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock worth $26,000 after buying an additional 2,870 shares during the last quarter. Osaic Holdings Inc. lifted its holdings in Certara by 50.7% in the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after acquiring an additional 1,175 shares during the last quarter. Tower Research Capital LLC TRC grew its position in Certara by 499.5% in the second quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock worth $69,000 after acquiring an additional 4,930 shares during the period. Pacer Advisors Inc. increased its stake in Certara by 28.1% during the first quarter. Pacer Advisors Inc. now owns 13,093 shares of the company’s stock worth $75,000 after acquiring an additional 2,871 shares during the last quarter. Finally, Chicago Partners Investment Group LLC acquired a new stake in Certara during the first quarter worth $78,000. 73.96% of the stock is currently owned by institutional investors and hedge funds.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.